ATE407209T1 - Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen - Google Patents

Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen

Info

Publication number
ATE407209T1
ATE407209T1 AT01944811T AT01944811T ATE407209T1 AT E407209 T1 ATE407209 T1 AT E407209T1 AT 01944811 T AT01944811 T AT 01944811T AT 01944811 T AT01944811 T AT 01944811T AT E407209 T1 ATE407209 T1 AT E407209T1
Authority
AT
Austria
Prior art keywords
antibodies
diagnostic
cryptosporidium parvum
medical compounds
parvum antigens
Prior art date
Application number
AT01944811T
Other languages
English (en)
Inventor
J Simonsen
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Application granted granted Critical
Publication of ATE407209T1 publication Critical patent/ATE407209T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01944811T 2000-06-15 2001-06-15 Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen ATE407209T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21208300P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
ATE407209T1 true ATE407209T1 (de) 2008-09-15

Family

ID=22789489

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01944811T ATE407209T1 (de) 2000-06-15 2001-06-15 Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen
AT06011952T ATE453714T1 (de) 2000-06-15 2001-06-15 Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06011952T ATE453714T1 (de) 2000-06-15 2001-06-15 Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen

Country Status (8)

Country Link
US (4) US6808900B2 (de)
EP (2) EP1294889B1 (de)
AT (2) ATE407209T1 (de)
AU (1) AU6720601A (de)
CA (1) CA2411949C (de)
DE (2) DE60140972D1 (de)
ES (1) ES2313962T3 (de)
WO (1) WO2001096370A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
EP1968630B1 (de) 2005-12-29 2018-01-24 Boehringer Ingelheim Vetmedica, Inc. Multivalente immunogene pcv2-zusammensetzungen
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
EP2099927A4 (de) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed Verfahren zur reduzierung von mit schweine-circovirus assoziierten krankheitsausbrüchen
EP2859900A1 (de) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Wirksames Verfahren zur Behandlung von Infektionen mit dem porcinen Circovirus und Lawsonia intracellularis
JP5200223B2 (ja) * 2006-12-15 2013-06-05 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２抗原によるブタの処置
EP1941903A1 (de) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxe und Behandlung von PRDC
EP1958644A1 (de) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Vorbeugung und Behandlung von subklinischer PCVD
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009088950A2 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 virus like particle with foreign amino acid insertion
KR20100113582A (ko) * 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CN103503841B (zh) * 2013-09-29 2016-01-20 捷胜海洋装备股份有限公司 一种浮球牵引机的牵引结构
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024649A1 (en) 1992-05-29 1993-12-09 The Regents Of The University Of California Cryptosporidium polypeptides, nucleic acid, vectors and methods of use
ATE195347T1 (de) * 1992-10-02 2000-08-15 Res Corp Technologies Inc Methoden der erhöhung der sekretion von überexpremierten proteinen
US5591434A (en) 1993-05-26 1997-01-07 The United States Of America As Represented By The Secretary Of Agriculture DNA sequence encoding surface protein of cryptosporidium parvum
EP0961547A4 (de) * 1996-08-23 2002-08-14 Univ North Carolina State Neutralisationsempfindliche epitrope von cryptosporidiumparvum

Also Published As

Publication number Publication date
CA2411949A1 (en) 2001-12-20
US8241871B2 (en) 2012-08-14
ATE453714T1 (de) 2010-01-15
EP1294889B1 (de) 2008-09-03
US20020034516A1 (en) 2002-03-21
EP1762620A3 (de) 2007-04-04
US20050064553A1 (en) 2005-03-24
US7288621B2 (en) 2007-10-30
EP1762620B1 (de) 2009-12-30
CA2411949C (en) 2012-05-22
WO2001096370A2 (en) 2001-12-20
WO2001096370A9 (en) 2002-09-19
US7850972B2 (en) 2010-12-14
AU6720601A (en) 2001-12-24
WO2001096370A3 (en) 2003-01-03
EP1294889A2 (de) 2003-03-26
US20080299143A1 (en) 2008-12-04
DE60140972D1 (de) 2010-02-11
ES2313962T3 (es) 2009-03-16
US6808900B2 (en) 2004-10-26
US20120045464A1 (en) 2012-02-23
DE60135655D1 (de) 2008-10-16
EP1762620A2 (de) 2007-03-14

Similar Documents

Publication Publication Date Title
ATE407209T1 (de) Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
DE60027890D1 (de) Streptococcus pneumoniae proteine und impfstoffe
AU9063801A (en) Methods and compositions for diseases associated with amyloidosis
DE60237778D1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
TR200200633T2 (tr) Yeni streptococcus antijenleri
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
MXPA03000103A (es) Antigenos de streptococcus.
NO20030252L (no) Forbindelser og fremgangsmåter for behandling og diagnostikk av klamydiainfeksjon
DE60032486D1 (de) Prion protein peptide und deren verwendung
IL141775A0 (en) Aglyco products and methods of use
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
WO2005007673A3 (en) Immunogenic peptides
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
WO2002024739A3 (en) Spas-1 cancer antigen
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE313560T1 (de) Therapeutische anti-cytomegalovirus verbindungen
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties